Improving CAR T-Cell Therapies for Multiple Myeloma: Thomas G. Martin, MD
The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed CAR T-cell therapies and safety signals of cilta-cel.
Ciltacabtagene autoleucel (cilta-cel) has continued to produce deep and durable responses in heavily-pretreated patients with multiple myeloma, as seen in data from the phase 1/2 CARTITUDE-1 study (NCT03548207).1,2
Data from the CARTITUDE-1 study were presented at the 63rd Annual American Society of Hematology (ASH) Meeting, December 11-14, 2021,, by Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California San Francisco, and co-leader, Cancer Immunology & Immunotherapy Program, Helen Diller Family Comprehensive Cancer Center.
Further data on cilta-cel, as an earlier line of therapy in patients with only 1 to 3 prior lines of therapy, were also presented at ASH 2021. These data were from the CARTITUDE-2 study (NCT04133636), which found that progression-free survival (PFS) at 6 months was 90% (95% CI, 65.6–97.4).
CGTLive spoke with Martin to learn more about cilta-cel. He discussed safety signals seen in the CARTITUDE-1 study, including the development of secondary hematologic malignancies. He also discussed future research that needs to be done with cilta-cel, including targeting selections and determining its place in the treatment landscape of multiple myeloma.
